Daiichi Sankyo (OTCMKTS:DSNKY) Releases FY 2026 Earnings Guidance

Daiichi Sankyo (OTCMKTS:DSNKY) updated its FY 2026 earnings guidance on Friday. The company provided earnings per share guidance of 0.870-0.870 for the period, compared to the consensus EPS estimate of 1.040. The company issued revenue guidance of $14.7 billion-$14.7 billion, compared to the consensus revenue estimate of $13.4 billion.

Daiichi Sankyo Stock Up 3.1%

Shares of DSNKY opened at $18.23 on Friday. Daiichi Sankyo has a fifty-two week low of $14.98 and a fifty-two week high of $27.50. The company’s fifty day moving average is $16.52 and its two-hundred day moving average is $17.74. The firm has a market cap of $33.96 billion, a PE ratio of 19.39, a price-to-earnings-growth ratio of 3.10 and a beta of -0.17. The company has a quick ratio of 1.64, a current ratio of 2.42 and a debt-to-equity ratio of 0.18.

Daiichi Sankyo (OTCMKTS:DSNKY) last issued its earnings results on Monday, May 11th. The company reported $0.15 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.18). Daiichi Sankyo had a return on equity of 15.75% and a net margin of 12.32%.The firm had revenue of $3.76 billion during the quarter, compared to analysts’ expectations of $3.74 billion. Daiichi Sankyo has set its FY 2026 guidance at 0.910-0.910 EPS. Analysts forecast that Daiichi Sankyo will post 0.96 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on DSNKY shares. Jefferies Financial Group lowered Daiichi Sankyo from a “buy” rating to a “hold” rating in a research note on Thursday. Zacks Research raised shares of Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a research report on Tuesday, May 5th. Two analysts have rated the stock with a Hold rating, According to data from MarketBeat, Daiichi Sankyo presently has a consensus rating of “Hold”.

About Daiichi Sankyo

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody?drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.